Table 2.
Demographics and baseline characteristics
| Placebo (n = 4904) | EMPA 10 mg (n = 4858) | EMPA 25 mg (n = 5057) | EMPA 10/25 mg (n = 10,177) | |
|---|---|---|---|---|
| Male, n (%) | 3119 (63.6) | 3094 (63.7) | 3249 (64.2) | 6529 (64.2) |
| Age, years | 60.5 (9.8) | 60.3 (9.7) | 60.4 (9.8) | 60.3 (9.7) |
| Age groups, years (%) | ||||
| < 65 | 3197 (65.2) | 3168 (65.2) | 3293 (65.1) | 6639 (65.2) |
| 65 to < 75 | 1377 (28.1) | 1390 (28.6) | 1426 (28.2) | 2887 (28.4) |
| 75 to < 85 | 318 (6.5) | 290 (6.0) | 327 (6.5) | 630 (6.2) |
| ≥ 85 | 12 (0.2) | 10 (0.2) | 11 (0.2) | 21 (0.2) |
| Race, n (%) | ||||
| White | 3044 (62.1) | 3256 (67.0) | 3346 (66.2) | 6602 (64.9) |
| Asian | 1347 (27.5) | 1252 (25.8) | 1349 (26.7) | 2601 (25.6) |
| Black/African–American | 279 (5.7) | 213 (4.4) | 219 (4.3) | 512 (5.0) |
| Othera | 51 (1.0) | 50 (1.0) | 51 (1.0) | 101 (1.0) |
| Missing | 183 (3.7) | 87 (1.8) | 92 (1.8) | 361 (3.5) |
| Region, n (%) | ||||
| Europe | 1821 (37.1) | 1939 (39.9) | 2013 (39.8) | 3952 (38.8) |
| North America | 1057 (21.6) | 1056 (21.7) | 1083 (21.4) | 2219 (21.8) |
| Latin America | 474 (9.7) | 503 (10.4) | 505 (10.0) | 1008 (9.9) |
| Africa/Middle East | 132 (2.7) | 129 (2.7) | 141 (2.8) | 270 (2.7) |
| Asia | 1420 (29.0) | 1231 (25.3) | 1315 (26.0) | 2728 (26.8) |
| Time since diabetes diagnosis, years, n (%) | ||||
| ≤ 1 | 259 (5.3) | 295 (6.1) | 308 (6.1) | 616 (6.1) |
| > 1 to ≤ 5 | 1077 (22.0) | 1048 (21.6) | 1100 (21.8) | 2216 (21.8) |
| > 5 | 3553 (72.5) | 3500 (72.0) | 3633 (71.8) | 7314 (71.9) |
| Missing | 15 (0.3) | 15 (0.3) | 16 (0.3) | 31 (0.3) |
| BMI, kg/m2b | 30.4 (5.5) | 30.5 (5.5) | 30.5 (5.5) | 30.5 (5.6) |
| eGFR, ml/min/1.73 m2, n (%)c | ||||
| ≥ 90 | 1933 (39.4) | 1998 (41.1) | 2041 (40.4) | 4177 (41.0) |
| ≥ 60 to < 90 | 2123 (43.3) | 2203 (45.3) | 2155 (42.6) | 4477 (44.0) |
| ≥ 45 to < 60 | 519 (10.6) | 464 (9.6) | 535 (10.6) | 1003 (9.9) |
| ≥ 30 to < 45 | 277 (5.6) | 182 (3.7) | 262 (5.2) | 445 (4.4) |
| < 30 | 52 (1.1) | 10 (0.2) | 61 (1.2) | 71 (0.7) |
| Missing | 0 | 1 (< 0.1) | 3 (0.1) | 4 (< 0.1) |
Data are mean (SD) unless otherwise indicated
BMI body mass index, eGFR estimated glomerular filtration rate, EMPA empagliflozin, SD standard deviation
aAmerican Indian/Alaska Native/Hawaiian/Pacific Islander
bPlacebo, n = 4883; EMPA 10 mg, n = 4838; EMPA 25 mg, n = 5038; EMPA 10/25 mg, n = 10,138
cPlacebo, n = 4904; EMPA 10 mg, n = 4857; EMPA 25 mg, n = 5054; EMPA 10/25 mg, n = 10,173